BioTech | Cambridge, Mass.
Bio-Tech Startup Catamaran Bio Launches with $42 Million Financing for CAR-NK Solid Tumor Therapies
Catamaran Bio, a biotech startup creating allogeneic CAR-NK cell cancer treatment therapies, today announced its launching with a $42 million Series A round led by Sofinnova Partners and Lightstone Ventures. Founding investor SV Health Investors also participated along with new investors Takeda Ventures and Astellas Venture Management. Funds will advance the company’s lead chimeric antigen receptor (CAR)-NK cell therapy programs and expand the company’s TAILWIND™ Platform, an integrated, proprietary technology suite to design, genetically engineer, and manufacture allogeneic CAR-NK cell therapies. [Full story]